IDOSE TR Drug Patent Profile
✉ Email this page to a colleague
When do Idose Tr patents expire, and when can generic versions of Idose Tr launch?
Idose Tr is a drug marketed by Glaukos and is included in one NDA. There are two patents protecting this drug.
This drug has fifty patent family members in seven countries.
The generic ingredient in IDOSE TR is travoprost. There are fifteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the travoprost profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Idose Tr
A generic version of IDOSE TR was approved as travoprost by CHARTWELL RX on March 1st, 2013.
Summary for IDOSE TR
| International Patents: | 50 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for IDOSE TR |
| What excipients (inactive ingredients) are in IDOSE TR? | IDOSE TR excipients list |
| DailyMed Link: | IDOSE TR at DailyMed |
Pharmacology for IDOSE TR
| Drug Class | Prostaglandin Analog |
Anatomical Therapeutic Chemical (ATC) Classes for IDOSE TR
US Patents and Regulatory Information for IDOSE TR
IDOSE TR is protected by two US patents and one FDA Regulatory Exclusivity.
Patents protecting IDOSE TR
Implants with controlled drug delivery features and methods of using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
Implants with controlled drug delivery features and methods of using same
Patent Number: ⤷ Try a Trial
Patent Expiration: ⤷ Try a Trial
FDA Regulatory Exclusivity protecting IDOSE TR
NEW PRODUCT
Exclusivity Expiration: ⤷ Try a Trial
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaukos | IDOSE TR | travoprost | IMPLANT;INTRACAMERAL | 218010-001 | Dec 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Glaukos | IDOSE TR | travoprost | IMPLANT;INTRACAMERAL | 218010-001 | Dec 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
| Glaukos | IDOSE TR | travoprost | IMPLANT;INTRACAMERAL | 218010-001 | Dec 13, 2023 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for IDOSE TR
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Novartis Europharm Limited | Izba | travoprost | EMEA/H/C/002738 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1). Decrease of elevated intraocular pressure in paediatric patients aged 3 years to < 18 years with ocular hypertension or paediatric glaucoma. |
Authorised | no | no | no | 2014-02-20 | |
| Novartis Europharm Limited | Travatan | travoprost | EMEA/H/C/000390 Decrease of elevated intraocular pressure in adult patients with ocular hypertension or open-angle glaucoma (see section 5.1).Decrease of elevated intraocular pressure in paediatric patients aged 2 months to < 18 years with ocular hypertension or paediatric glaucoma (see section 5.1). |
Authorised | no | no | no | 2001-11-27 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for IDOSE TR
See the table below for patents covering IDOSE TR around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2014237278 | Implants with controlled drug delivery features and methods of using same | ⤷ Try a Trial |
| Australia | 2014348667 | Ocular implants configured to store and release stable drug formulations | ⤷ Try a Trial |
| Japan | 2012527318 | ⤷ Try a Trial | |
| European Patent Office | 3068371 | IMPLANTS OCULAIRES CONÇUS POUR STOCKER ET LIBÉRER DES FORMULATIONS DE MÉDICAMENTS STABLES (OCULAR IMPLANTS CONFIGURED TO STORE AND RELEASE STABLE DRUG FORMULATIONS) | ⤷ Try a Trial |
| Japan | 6043834 | ⤷ Try a Trial | |
| Canada | 3186189 | IMPLANT OCULAIRE A ELUTION DE MEDICAMENT (DRUG ELUTING OCULAR IMPLANT) | ⤷ Try a Trial |
| World Intellectual Property Organization (WIPO) | 2012071476 | ⤷ Try a Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for IDOSE TR
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1514548 | CA 2014 00038 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROST; REG. NO/DATE: EU/1/01/199/001-002 20011127 |
| 1920764 | C01920764/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROST; REGISTRATION NUMBER/DATE: SWISSMEDIC 55910 22.05.2002 |
| 1514548 | PA2014029 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROSTUM; REGISTRATION NO/DATE: EU/1/01/199/001 - EU/1/01/199/002 20011129 |
| 1920764 | PA2012017,C1920764 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127 |
| 1920764 | 12C0045 | France | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001 20011127 |
| 1920764 | SPC/GB12/038 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROST; REGISTERED: UK EU/1/01/199/001-002 20011129 |
| 1920764 | PA2012017 | Lithuania | ⤷ Try a Trial | PRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - HIPAA-ready chat for life sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
